TRPC3-mediated Ca2+ influx contributes to Rac1-mediated production of reactive oxygen species in MLP-deficient mouse hearts

Biochemical and Biophysical Research Communications

Volumn 409, Issue 1, 2011, Pages 108-113

  Kitajima, Naoyuki ^a   Watanabe, Kunihiro ^a   Morimoto, Sachio ^b   Sato, Yoji ^c   Kiyonaka, Shigeki ^d   Hoshijima, Masahiko ^e   Ikeda, Yasuhiro ^f   Nakaya, Michio ^a   Ide, Tomomi ^b   Mori, Yasuo ^d   Kurose, Hitoshi ^a   Nishida, Motohiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dilated cardiomyopathy; Muscle LIM protein; Rac; Reactive oxygen species; Transient receptor potential channel

Indexed keywords

CALCIUM; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; DIPEPTIDYL CARBOXYPEPTIDASE; ETHYL 1 [4 (2,3,3 TRICHLOROACRYLAMIDE)PHENYL] 5 (TRIFLUOROMETHYL) 1H PYRAZOLE 4 CARBOXYLATE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCEROL 2 ACETATE 1 OLEATE; MYOSIN HEAVY CHAIN BETA; PYRAZOLE DERIVATIVE; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSCRIPTION FACTOR RUNX2; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL 3; TRANSIENT RECEPTOR POTENTIAL CHANNEL 5; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; TRANSIENT RECEPTOR POTENTIAL CHANNEL 7; UNCLASSIFIED DRUG; ETHYL 1 (4 (2*3*3 TRICHLOROACRYLAMIDE)PHENYL) 5 (TRIFLUOROMETHYL) 1H PYRAZOLE 4 CARBOXYLATE; ETHYL-1-(4-(2*3*3-TRICHLOROACRYLAMIDE)PHENYL)-5-(TRIFLUOROMETHYL)-1H-PYRAZOLE-4-CARBOXYLATE; MUSCLE LIM PROTEIN; MUSCLE PROTEIN; NEUROPEPTIDE; RAC PROTEIN; RAC1 PROTEIN, MOUSE; TRANSIENT RECEPTOR POTENTIAL CHANNEL C;

ANIMAL CELL; ARTICLE; CALCIUM SIGNALING; CALCIUM TRANSPORT; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART DILATATION; HEART MUSCLE CELL; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; DRUG ANTAGONISM; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; METABOLISM; MOUSE MUTANT; RAT;

MURINAE; MUS; RATTUS;

ANIMALS; CALCIUM; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CARDIOMYOPATHY, DILATED; MICE; MICE, MUTANT STRAINS; MUSCLE PROTEINS; MYOCARDIUM; NEUROPEPTIDES; PYRAZOLES; RAC GTP-BINDING PROTEINS; RATS; REACTIVE OXYGEN SPECIES; TRPC CATION CHANNELS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79956194828     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.04.124     Document Type: Article

References (40)

1. Towbin J.A., Lowe A.M., Colan S.D., et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006, 296:1867-1876.
2. Maclellan W.B., Lusis A. Dilated cardiomyopathy: learning to live with yourself. Nat. Med. 2003, 9:1455-1456.
3. Grunig E., Tasman J.A., Kucherer H., et al. Frequency and phenotypes of familial dilated cardiomyopathy. J. Am. Coll. Cardiol. 1998, 31:186-194.
4. Towbin J.A., Bowles N.E. The failing heart. Nat. Insight rev. articles 2002, 415:227-233.
5. Du C.-K., Morimoto S., Nishii K., et al. Knock-in model of dilated cardiomyopathy caused by troponin mutation. Circ. Res. 2007, 101:185-194.
6. Arber S., Halder G., Caroni P. Muscle LIM protein, a novel essential regulator of myogenesis, promotes myogenic differentiation. Cell 1994, 79:221-231.
7. Arber S., Hunter J.J., Ross J., et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 1997, 88:393-403.
8. Knöll R., Hoshijima M., Hoffman H.M., et al. The cardiac mechanical stretch sensor machinery involves a Z-disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 2002, 111:943-955.
9. Knöll R., Kostin S., Klede S., et al. A common MLP (muscle LIM protein) variant is associated with cardiomyopathy. Circ. Res. 2010, 106:695-704.
10. Yamamoto R., Akazawa H., Ito K., et al. Angiotensin II type 1a receptor signals are involved in the progression of heart failure in MLP-deficient mice. Circ. J. 2007, 71:1958-1964.
11. Rockman H.A., Chien K.R., Choi D.-J., et al. Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc. Natl. Acad. Sci. USA 1998, 95:7000-7005.
12. Wang X., Culotta V.C., Klee C.B. Superoxide dismutase protects calcineurin from inactivation. Nature 1996, 383:434-437.
13. Toko H., Takahashi H., Kayama Y., et al. Ca2+/calmodulin-dependent kinase IIδ causes heart failure by accumulation of p53 in dilated cardiomyopathy. Circulation 2010, 122:891-899.
14. Maack C., Kartes T., Kilter H., et al. Oxygen free radical release in human failing myocardium is associated with increased activity of Rac1-GTPase and represents a target for statin treatment. Circulation 2003, 108:1567-1574.
15. Montell C., Rubin G.M. Molecular characterization of the Drosophila trp locus: a putative integral membrane protein required for phototransduction. Neuron 1989, 2:1313-1323.
16. Nishida M., Hara Y., Yoshida T., et al. TRP channels: molecular diversity and physiological function. Microcirculation 2006, 13:535-550.
17. Nishida M., Kurose H. Roles of TRP channels in the development of cardiac hypertrophy. Naunyn-Schmiedeberg's Arch. Pharmacol. 2008, 378:395-406.
18. Bush E.W., Hood D.B., Papst P.J., et al. Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling. J. Biol. Chem. 2006, 281:33487-33496.
19. Kuwahara K., Wang Y., McAnally J., et al. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J. Clin. Invest. 2006, 116:3114-3126.
20. Seth M., Zhang Z.S., Mao L., et al. TRPC1 channels are critical for hypertrophic signaling in the heart. Circ. Res. 2009, 105:1023-1030.
21. Onohara N., Nishida M., Inoue R., et al. TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy. EMBO J. 2006, 25:5305-5316.
22. Kiyonaka S., Kato K., Nishida M., et al. Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound. Proc. Natl. Acad. Sci. USA 2009, 106:5400-5405.
23. Heineke J., Ruetten H., Willenbockel C., et al. Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc. Proc. Natl. Acad. Sci. USA 2005, 102:1655-1660.
24. Nishida M., Sato Y., Uemura A., et al. P2Y6 receptor-Gα12/13 signalling in cardiomyocytes triggers pressure overload-induced cardiac fibrosis. EMBO J. 2008, 27:3104-3115.
25. Nishida M., Maruyama Y., Tanaka R., et al. Gαi and Gαo are target proteins of reactive oxygen species. Nature 2000, 408:492-495.
26. Nishida M., Watanabe K., Sato Y., et al. Phosphorylation of TRPC6 channels at Thr69 is required for anti-hypertrophic effects of phosphodiesterase 5 inhibition. J. Biol. Chem. 2010, 285:13244-13253.
27. Fujii T., Onohara N., Maruyama Y., et al. Gα12/13-mediated production of reactive oxygen species is critical for angiotensin receptor-induced NFAT activation in cardiac fibroblasts. J. Biol. Chem. 2005, 280:23041-23047.
28. Granfeldt D., Samuelsson M., Karlsson A. Capacitative Ca2+ influx and activation of the neutrophil respiratory burst. Different regulation of plasma membrane-and granule-localized NADPH-oxidase. J. Leukoc. Biol. 2002, 71:611-617.
29. Graham D.B., Robertson C.M., Bautista J., et al. Neutrophil-mediated oxidative burst and host defense are controlled by a Vav-PLCγ2 signaling axis in mice. J. Clin. Invest. 2007, 117:3445-3452.
30. Li J.M., Gall N.P., Grieve D.J., et al. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 2002, 40:477-484.
31. Ago T., Kuroda J., Pain J., et al. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ. Res. 2010, 106:1253-1264.
32. Sumimoto H. Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J. 2008, 275:3249-3277.
33. Nishida M., Sugimoto K., Hara Y., et al. Amplification of receptor signaling by Ca2+ entry-mediated translocation and activation of PLCγ2 in B lymphocytes. EMBO J. 2003, 22:4677-4688.
34. Numaga T., Nishida M., Kiyonaka S., et al. Ca2+ influx and protein scaffolding via TRPC3 sustain PKCβ and ERK activation in B cells. J. Cell. Sci. 2010, 123:927-938.
35. Zorov D.B., Filburn C.R., Klotz L.O., et al. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J. Exp. Med. 2000, 192:1001-1014.
36. Brady N.R., Hamacher-Brady A., Westerhoff H.V., et al. A wave of reactive oxygen species (ROS)-induced ROS release in a sea of excitable mitochondria. Antioxid. Redox. Signal. 2006, 8:1651-1665.
37. Malhotra R., D'Souza K.M., Staron M.L., et al. Gαq-mediated activation of GRK2 by mechanical stretch in cardiac myocytes: the role of protein kinase C. J. Biol. Chem. 2010, 285:13748-13760.
38. Molkentin J.D., Lu J.-R., Antos C.L., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228.
39. Passier R., Zeng H., Frey N., et al. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J. Clin. Invest. 2000, 105:1395-1406.
40. Sayen M.R., Gustafsson A.B., Sussman M.A., et al. Calcineurin transgenic mice have mitochondrial dysfunction and elevated superoxide production. Am. J. Physiol. Cell Physiol. 2003, 284:C562-570.